ACTRN12619001062112已完成1 期
A Phase 1, Bioequivalence Trial Evaluating the Pharmacokinetic and Pharmacodynamic Biosimilarity of SBS6002 Versus Neulasta® Following Subcutaneous Administration to Healthy Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •Subjects enrolled in this study will be members of the community at large. The recruitment advertisements may use various media types. Subjects must meet all of the following criteria to be included in the study:
- •1)Male, non-smoker or social smoker.
- •2)Healthy as defined by:
- •a)the absence of clinically significant illness and surgery within 4 weeks prior to dosing. Inclusion pre-dosing is at the discretion of the Investigator.
- •b)the absence of clinically significant history of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
- •c)absence of febrile or infectious illness within 1 week prior to dosing.
- •3)Provide signed written informed consent prior to the initiation of any study-specific procedures.
- •4)Willing and able to comply with the requirements of the protocol and be available for the planned duration of the trial.
排除标准
- •Subjects to whom any of the following applies will be excluded from the study:
- •1)Any clinically significant abnormality at physical examination at screening or on Day -1 of Period 1
- •2)Any clinically significant abnormal hematology, biochemistry and other laboratory test results found at screening.
- •3)Positive test for hepatitis B, hepatitis C, or HIV at screening.
- •4)Positive urine drug screen at screening or on Day -1 of Period 1.
- •5)History of allergic reactions or hypersensitivity to pegfilgrastim, filgrastim, E. coli-derived proteins, PEGylated proteins, or to any excipients of the study drug.
- •6)Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
- •7)Clinically significant ECG abnormalities or vital sign abnormalities at screening.
- •8)History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening or positive alcohol test at screening or on Day -1 of Period 1.
- •9)History of significant drug abuse within one year prior to screening or use of soft drugs within 3 months prior to the screening visit or hard drugs within 1 year prior to screening.
- •10)Participation in any other investigational clinical study in which administration of an investigational study drug occurred within 30 days or 5 half-lives of the product (whichever is the longest) prior to screening.
- •11)Use of medication, other than topical products without significant systemic absorption.
- •12)Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.
- •13)Any past exposure to recombinant human G-CSF products and/or a known history of prior treatment with blood-cell colony stimulating factors, interleukins or interferons.
- •14)History of sickle cell trait or sickle cell disease.
- •15)History of pulmonary infiltrate or pneumonia within 6 months before the screening visit.
- •16)Signs or symptoms of chronic obstructive pulmonary disease.
- •17)Splenomegaly at screening or prior to Day 1.
- •18)Hereditary fructose intolerance.
- •19)Tattoos covering the potential study drug injection site.
研究者
相似试验
已完成
不适用
A Phase I, open-label trial to investigate the pharmacokinetic interaction between TMC125 and two antifungal agents (fluconazole and voriconazole), all at steady-state in healthy subjects.AIDSHIV10021460NL-OMON32571Tibotec Pharmaceuticals Ltd, EastGate Village, Eastgate, Little Island, CO Cork, Ireland, In Nederland vertegenwoordigd door Janssen-Cilag B.V.18
未知
1 期
DMB-3113 Phase IHealthy volunteersJPRN-jRCT2080223335Meiji Seika Pharma Co., Ltd.180
撤回
不适用
A Phase I, open-label study to investigate the pharmacokinetics of GLPG2451 given as two doses of a capsule formulation in healthy subjectsthick mucus disease10027664Cystic fibrosismucoviscidosisNL-OMON45502Galapagos SAS12
已完成
1 期
Pivotal in vivo bioequivalence study of comparing Eumovate cream to clobetasone butyrate cream applied to the skin in healthy male and female volunteers.A pivotal in vivo bioequivalence study conducted in healthy volunteers with no health condition or problem studied.This study is being conducted in healthy volunteers who are not being treated for the conditions that Eumovate cream is indicated for. Eumovate cream is indicated for the short term (up to 7 days) treatment of the milder form of eczema, dermatitis and other steroid responsive skin conditions which do not require the use of a more active topical corticosteroid in children and adults.A pivotal in vivo bioequivalence study conducted in healthy volunteers with no health condition or problem studied.This study is being conducted in healthy volunteers who are not being treated for the conditions that Eumovate cream is indicated for.Eumovate cream is indicated for the short term (up to 7 days) treatment of the milder form of eczema, dermatitis and other steroid responsive skin conditions which do not require the use of a more active topical corticosteroid in children and adults.Skin - Dermatological conditionsACTRN12615000815561Zenith Technology Corp Ltd90
已完成
不适用
A Study to Evaluate Safety and Pharmacokinetic Characteristics after Administration of the SJP003 in Healthy Male VolunteersEndocrine, nutritional and metabolic diseaseKCT0004019Samjin Pharmaceutical40